Effect of EBV infection on outcome in XLP
| . | Median age 1st manifestation (y) . | Median survival age (y) . |
|---|---|---|
| EBV+ | 4 (0.5-40) | 6 (0.5-40) |
| FIM | 3 (0.5-40) | 4 (0.5-40) |
| Dysgammaglobulinemia | 6 (0.5-32) | 14 (0.5-38) |
| Lymphoproliferative disease | 5 (2-19) | 6 (2-32) |
| Aplastic anemia | 6 (2-24) | 12 (2-27) |
| EBV− | 6 (0-34) | 6.55-150 (1-41) |
| Dysgammaglobulinemia | 4.5 (0.1-34) | 19 (4-41) |
| Lymphoproliferative disease | 8 (3-33) | 17 (4-39) |
| Aplastic anemia | 1, 11 | 7, 14 |
| . | Median age 1st manifestation (y) . | Median survival age (y) . |
|---|---|---|
| EBV+ | 4 (0.5-40) | 6 (0.5-40) |
| FIM | 3 (0.5-40) | 4 (0.5-40) |
| Dysgammaglobulinemia | 6 (0.5-32) | 14 (0.5-38) |
| Lymphoproliferative disease | 5 (2-19) | 6 (2-32) |
| Aplastic anemia | 6 (2-24) | 12 (2-27) |
| EBV− | 6 (0-34) | 6.55-150 (1-41) |
| Dysgammaglobulinemia | 4.5 (0.1-34) | 19 (4-41) |
| Lymphoproliferative disease | 8 (3-33) | 17 (4-39) |
| Aplastic anemia | 1, 11 | 7, 14 |
P < .05.